Pfizer spin-off plans stand to damage credit rating

Pfizer is jeopardizing its credit rating as it considers selling units that account for about 27 percent of its $67.8 billion in annual sales and using proceeds for share buybacks, ratings experts said. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.